Advanced search
Publication Cover
The World Journal of Biological Psychiatry Volume 11, 2010 - Issue 2-2
Submit an article Journal homepage
780
Views
49
CrossRef citations to date
0
Altmetric
Review Articles

Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists

Patrik Roser Research Group Clinical and Experimental Psychopathology, Department of General and Social Psychiatry ZH West, Psychiatric University Hospital Zurich, Zurich, Switzerland
,
Franz X. Vollenweider Research Group Neuropsychopharmacology and Brain Imaging & Heffter Research Center, Clinic for Affective Disorders and General Psychiatry ZH East, Psychiatric University Hospital Zurich, Zurich, Switzerland
&
Wolfram Kawohl Research Group Clinical and Experimental Psychopathology, Department of General and Social Psychiatry ZH West, Psychiatric University Hospital Zurich, Zurich, SwitzerlandCorrespondence[email protected]
, MD
Pages 208-219 | Received 10 Dec 2007, Accepted 09 Jan 2008, Published online: 10 Mar 2010

Citations (49)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Joanna Makowiecka & Karolina Wielgus. (2014) Therapeutic Potential of Cannabinoids—Retrospective and Historical Developments. Journal of Natural Fibers 11:3, pages 185-198.
Read now
Peter J McKenna & Ann M Mortimer. (2014) Current and future treatment modalities in schizophrenia: novel antipsychotic drugs and cognitive therapy. Expert Review of Neurotherapeutics 14:1, pages 67-73.
Read now
Falko Biedermann & W Wolfgang Fleischhacker. (2011) Emerging drugs for schizophrenia. Expert Opinion on Emerging Drugs 16:2, pages 271-282.
Read now

Articles from other publishers (46)

T. Dixon & K. S. Cadenhead. (2023) Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial. Trials 24:1.
Crossref
Ivan A. RossIvan A. Ross. 2023. Plant-Based Therapeutics, Volume 1. Plant-Based Therapeutics, Volume 1 185 248 .
Eef L. Theunissen, Johannes T. Reckweg, Nadia R. P. W. Hutten, Kim P. C. Kuypers, Stefan W. Toennes, Merja A. Neukamm, Sebastian Halter & Johannes G. Ramaekers. (2021) Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis. Psychopharmacology 239:5, pages 1251-1261.
Crossref
Rodrigo Ribeiro Alves Caiana, Cosme Silva Santos, Ronaldo Nascimento de Oliveira & Juliano Carlo Rufino Freitas. (2022) Scientific and Technological Prospecting of 1H-1,2,3-Triazoles. Current Organic Chemistry 26:3, pages 275-286.
Crossref
Claude Cyr, Mellar P. Davis, Danial Schecter & Paul DaeninckMellar P. Davis. 2022. Cannabis and Cannabinoid-Based Medicines in Cancer Care. Cannabis and Cannabinoid-Based Medicines in Cancer Care 41 89 .
Roberto Colangeli, G. Campbell Teskey & Giuseppe Di Giovanni. 2021. 5-HT Interaction with Other Neurotransmitters: Experimental Evidence and Therapeutic Relevance - Part A. 5-HT Interaction with Other Neurotransmitters: Experimental Evidence and Therapeutic Relevance - Part A 83 134 .
Caroline A. MacCallum, Lauren de Freitas & Shaohua Lu. 2021. Cannabinoids and Pain. Cannabinoids and Pain 271 280 .
Tibor Stark, Jana Ruda-Kucerova, Fabio Arturo Iannotti, Claudio D'Addario, Roberta Di Marco, Vladimir Pekarik, Eva Drazanova, Fabiana Piscitelli, Monica Bari, Zuzana Babinska, Giovanni Giurdanella, Martina Di Bartolomeo, Salvatore Salomone, Alexandra Sulcova, Mauro Maccarrone, Carsten T. Wotjak, Zenon StarcukJr.Jr., Filippo Drago, Raphael Mechoulam, Vincenzo Di Marzo & Vincenzo Micale. (2019) Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology 146, pages 212-221.
Crossref
Florence Hagenmuller, Karsten Heekeren, Patrik Roser, Helene Haker, Anastasia Theodoridou, Susanne Walitza, Wulf Rössler & Wolfram Kawohl. (2019) Early Somatosensory Processing Over Time in Individuals at Risk to Develop Psychosis. Frontiers in Psychiatry 10.
Crossref
Vincenzo Di Marzo. (2018) New approaches and challenges to targeting the endocannabinoid system. Nature Reviews Drug Discovery 17:9, pages 623-639.
Crossref
Amanda J. Sales, Carlos C. Crestani, Francisco S. Guimarães & Sâmia R.L. Joca. (2018) Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels. Progress in Neuro-Psychopharmacology and Biological Psychiatry 86, pages 255-261.
Crossref
A Busquets-Garcia, E Soria-Gómez, B Redon, Y Mackenbach, M Vallée, F Chaouloff, M Varilh, G Ferreira, P-V Piazza & G Marsicano. (2017) Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice. Molecular Psychiatry 22:11, pages 1594-1603.
Crossref
Rafael N. Ruggiero, Matheus T. Rossignoli, Jana B. De Ross, Jaime E. C. Hallak, Joao P. Leite & Lezio S. Bueno-Junior. (2017) Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. Frontiers in Pharmacology 8.
Crossref
Lirit N. Franks, Benjamin M. Ford & Paul L. Prather. (2016) Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity. Frontiers in Pharmacology 7.
Crossref
John MerrickBrian LaneTerri SebreeTony YakshCarol O'NeillStan L. Banks. (2016) Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid. Cannabis and Cannabinoid Research 1:1, pages 102-112.
Crossref
Tara L Crowell. (2016) Understanding Patients’ Process to Use Medical Marijuana. Journal of Patient Experience 3:3, pages 81-87.
Crossref
F. Markus Leweke, Juliane K. Mueller, Bettina Lange & Cathrin Rohleder. (2016) Therapeutic Potential of Cannabinoids in Psychosis. Biological Psychiatry 79:7, pages 604-612.
Crossref
David D Aguilar, Andrea Giuffrida & Daniel J Lodge. (2015) THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia. Journal of Psychopharmacology 30:2, pages 169-181.
Crossref
Paul F. Smith & Yiwen Zheng. (2016) Cannabinoids, cannabinoid receptors and tinnitus. Hearing Research 332, pages 210-216.
Crossref
晓凤 贾. (2016) Receptors and Related Drug Development for Schizophrenia: Research Advances. Pharmacy Information 05:02, pages 19-24.
Crossref
Amresh Shrivastava, Megan Johnston, Kristen Terpstra & Yves Bureau. (2015) Pathways to Psychosis in Cannabis Abuse. Clinical Schizophrenia & Related Psychoses 9:1, pages 30-35.
Crossref
Yiwen Zheng, Peter Reid & Paul F. Smith. (2015) Cannabinoid CB1 Receptor Agonists Do Not Decrease, but may Increase Acoustic Trauma-Induced Tinnitus in Rats. Frontiers in Neurology 6.
Crossref
Florence Hagenmuller, Karsten Heekeren, Anastasia Theodoridou, Susanne Walitza, Helene Haker, Wulf Rössler & Wolfram Kawohl. (2014) Early somatosensory processing in individuals at risk for developing psychoses. Frontiers in Behavioral Neuroscience 8.
Crossref
Samira S. Valvassori, Daniela V. Bavaresco, Giselli Scaini, Roger B. Varela, Emilio L. Streck, Marcos H. Chagas, Jaime E.C. Hallak, Antonio W. Zuardi, José A. Crippa & João Quevedo. (2013) Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain. Revista Brasileira de Psiquiatria 35:4, pages 380-386.
Crossref
André Twardowschy, Maria Angélica Castiblanco-Urbina, Andres Uribe-Mariño, Audrey Francisco Biagioni, Carlos José Salgado-Rohner, José Alexandre de Souza Crippa & Norberto Cysne Coimbra. (2013) The role of 5-HT 1A receptors in the anti-aversive effects of cannabidiol on panic attack-like behaviors evoked in the presence of the wild snake Epicrates cenchria crassus (Reptilia, Boidae) . Journal of Psychopharmacology 27:12, pages 1149-1159.
Crossref
A M McKillop, B M Moran, Y H A Abdel-Wahab & P R Flatt. (2013) Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice. British Journal of Pharmacology 170:5, pages 978-990.
Crossref
H. Bugra, E. Studerus, C. Rapp, C. Tamagni, J. Aston, S. Borgwardt & A. Riecher-Rössler. (2013) Cannabis use and cognitive functions in at-risk mental state and first episode psychosis. Psychopharmacology 230:2, pages 299-308.
Crossref
Wei-Xin Yuan, Li-Jun Heng, Jie Ma, Xing-Qin Wang, Li-Juan Qu, Li Duan, Jun-Jun Kang, Liang-Wei Chen & Guo-Dong Gao. (2013) Increased expression of cannabinoid receptor 1 in the nucleus accumbens core in a rat model with morphine withdrawal. Brain Research 1531, pages 102-112.
Crossref
Atsushi Saito, Michael D.L. Ballinger, Mikhail V. Pletnikov, Dean F. Wong & Atsushi Kamiya. (2013) Endocannabinoid system: Potential novel targets for treatment of schizophrenia. Neurobiology of Disease 53, pages 10-17.
Crossref
Rodrigo Ferretjans, Fabrício A. Moreira, Antônio L. Teixeira & João V. Salgado. (2012) The Endocannabinoid System and its Role in Schizophrenia: A Systematic Review of the Literature. Revista Brasileira de Psiquiatria 34, pages 163-193.
Crossref
Kerri A. Schoedel, Carol Addy, Bijan Chakraborty, Kim Rosko, Stephanie Dunbar, Andrea Maes, Nancy Chen, Selwyn Aubrey Stoch, John Wagner, Jeff Chodakewitz & Edward M. Sellers. (2012) Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist. Journal of Clinical Psychopharmacology 32:4, pages 492-502.
Crossref
Kyra-Verena Sendt, Giovanni Giaroli & Derek K. Tracy. (2012) Beyond Dopamine: Glutamate as a Target for Future Antipsychotics. ISRN Pharmacology 2012, pages 1-9.
Crossref
Matcheri S KeshavanMichael C DavisStephen R Marder. 2012. Pharmacological Treatments in Schizophrenia. Pharmacological Treatments in Schizophrenia 40 48 .
Simon Zhornitsky & Stéphane Potvin. (2012) Cannabidiol in Humans—The Quest for Therapeutic Targets. Pharmaceuticals 5:5, pages 529-552.
Crossref
J. Michael Bostwick. (2012) Blurred Boundaries: The Therapeutics and Politics of Medical Marijuana. Mayo Clinic Proceedings 87:2, pages 172-186.
Crossref
Patrik Roser, Ida S. Haussleiter, Hee-Jeong Chong, Christoph Maier, Wolfram Kawohl, Christine Norra & Georg Juckel. (2011) Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia. Psychopharmacology 218:4, pages 611-620.
Crossref
Victoria S Dalton, Leonora E Long, Cyndi Shannon Weickert & Katerina Zavitsanou. (2011) Paranoid Schizophrenia is Characterized by Increased CB1 Receptor Binding in the Dorsolateral Prefrontal Cortex. Neuropsychopharmacology 36:8, pages 1620-1630.
Crossref
Andreas M. Stadelmann, Georg Juckel, Larissa Arning, Jürgen Gallinat, Jörg T. Epplen & Patrik Roser. (2011) Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential. Neuroscience Letters 496:1, pages 60-64.
Crossref
Mark D. Black, Rachel J. Stevens, Nancy Rogacki, Robert E. Featherstone, Yaw Senyah, Odessa Giardino, Beth Borowsky, Jeanne Stemmelin, Caroline Cohen, Philippe Pichat, Michal Arad, Segev Barak, Amaya De Levie, Ina Weiner, Guy Griebel & Geoffrey B. Varty. (2010) AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology 215:1, pages 149-163.
Crossref
Falko Biedermann & W. Wolfgang Fleischhacker. (2011) Neue Ansätze in der pharmakologischen Behandlung der Schizophrenie. Psychiatrie und Psychotherapie 7:1, pages 11-19.
Crossref
Peter A. ClarkKevin CapuzziCameron Fick. (2011) Medical marijuana: Medical necessity versus political agenda. Medical Science Monitor 17:12, pages RA249-RA261.
Crossref
Ann M. Mortimer. 2011. Handbook of Schizophrenia Spectrum Disorders, Volume III. Handbook of Schizophrenia Spectrum Disorders, Volume III 23 49 .
Claire E. Ramsay & Michael T. Compton. 2011. Handbook of Schizophrenia Spectrum Disorders, Volume III. Handbook of Schizophrenia Spectrum Disorders, Volume III 289 320 .
Carolyn J Asher & Linda Gask. (2010) Reasons for illicit drug use in people with schizophrenia: Qualitative study. BMC Psychiatry 10:1.
Crossref
Joëlle Desfossés, Emmanuel Stip, Lahcen Ait Bentaleb & Stéphane Potvin. (2010) Endocannabinoids and Schizophrenia. Pharmaceuticals 3:10, pages 3101-3126.
Crossref
Rajiv Tandon, Henry A. Nasrallah & Matcheri S. Keshavan. (2010) Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future. Schizophrenia Research 122:1-3, pages 1-23.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.